Abivax SA raises €130m to advance obefazimod to Phase III
French Abivax SA has raised €130m capital led by TCGX to accelerate Phase III testing of its ulcerative colitis candidate obefazimod extend its cashflow.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
Paleo raised € 12 m in Series A financing round
Myoglobin producer Paleo NV has closed a € 12 m Series A round led by DSM Venturing and Planet A Ventures.
Minaris and LIfT BioSciences collaborate in cell therapy development
CDMO Minaris Regenerative Medicine GmbH is to manufacture the leukocyte infusion therapy N-LIfT for LIFT BioSciences.
PVH Corp joins fiber-to-fiber consortium
PVH Corp has joined fiber-to-fiber consortium that wants to make textile recycling sustainable by establishing standards for biorecycled textile fibre.
Free sugar linked to higher cardiovascular disease
A UK Biobank study suggests that higher intake of free sugars is associated with a higher risk to develop cardiovascular disease, UK researchers report in BMC Medicine.
Expansion of the Munich science line has started
The extension, which was celebrated with an official groundbreaking ceremony, will connect the IZB campus in Martinsried to the Munich subway system.
AMsilk scaling up through Evonik collaboration
Fermatation expert Evonik SE has entered into an agreement with the German recombinant silk producer AMSilk to produce industrial quantities of innovative, sustainable silk proteins.
HOOKIPA bags US$10m cancer milestone
HOOKIPA has received a US$10m milestone under its 2022 agreement with Roche to develop an arenaviral immunotherapy for KRAS-mutated cancers.
Cydar Medical Ltd raises €10.5m in Series A financing
Cambridge-based endovascular surgical AI specialist Cydar Medical has completed a €10.5m (£9.3m) Series A funding round led by Pembroke Venture Capital Trust
Evonetix extends Series B financing to US$54m
British Evonetix Ltd has added US$$24m to its existing US$30m Series B financing round. The new financing was led by existing investor Foresite Capital.